[February 27, 2015]

Research and Markets: Status Epilepticus - Pipeline Review, H1 2015 - 2 Companies (Ligand Pharmaceuticals, Inc. & Sage Therapeutics) & 8 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/72s5rk/status) has announced the addition of the "Status Epilepticus - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and moecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Ligand Pharmaceuticals, Inc.
• Sage Therapeutics

Drug Profiles

• ADD-405008
• fosphenytoin sodium
• SAGE-217
• SAGE-547
• SAGE-689
• SGE-102
• Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus
• TG-4155

For more information visit http://www.researchandmarkets.com/research/72s5rk/status

[ Back To TMCnet.com's Homepage ]